Despite these claims, the U.S. Food and Drug Administration says that Mylan has continued to report adequate supply of EpiPens in the U.S., and has not added EpiPen devices on its list of medical shortages.
Mylan, the company that manufactures EpiPen, says the shortage is due to manufacturing delays.
The FDA places drugs on its shortage list when the supply of all versions of a treatment are inadequate to meet current or projected demand, according to the agency. "The FDA is committed to working closely with the manufacturers to resolve all shortages as quickly as possible".
US regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.
The situation: Israel launched a missile strike on Syria
The official news agency SANA says Tuesday night's attack occurred in the countryside in Kisweh, just south of Damascus. Israeli war planes were targeting Syrian territories with rockets early on Thursday for the second time in the week.
First of all, people should carefully check their epinephrine auto-injectors supply, and if they're running low, they should get more before they actually run out. Pfizer said it was overcoming the manufacturing problems, saying it was increasing production. "However Mylan continues to release the product".
Allergic Living first reported on consumers experiencing difficulty filling prescriptions for EpiPen and the equivalent generic devices on April 24. Mylan shares were inactive in Wednesday premarket trade.
Patients who are having issues finding the product were advised to call Mylan Customer Relations at 800-796-9526 for assistance.
After Mylan bought the rights to sell EpiPens, it increased prices 550% - from $94 in 2007 to $608 in 2016.
"We don't have to depend upon a supplier for this particular drug", he said. The Company states that they are expediting shipment to wholesalers as soon as they receive supply from MMT.